There is a moment in every healthcare cycle where the market gets too focused on a single trial result and misses everything else building underneath it.
That is exactly where Gilead Sciences is right now.
GILD is up roughly 3.5% this morning after a Phase 3 HIV trial hit its key endpoints clean and Trodelvy won first-line approval for triple-negative breast cancer in both the U.S. and Europe. HSBC upgraded the stock to Buy just yesterday, raising its price target to $155 from $133. The upgrade was pointed and specific: HSBC argued the market is too pessimistic about Gilead’s HIV franchise, assuming a steeper decline from generic competition than the underlying data supports. Long-acting HIV therapies, they argued, could offset much of that pressure through better patient adherence. Roughly 60% of HIV patients have suboptimal adherence, and more than 40% take fewer than 80% of prescribed doses. A once-weekly or once-monthly regimen changes that math entirely.
Then there is Trodelvy. The FDA cleared it for first-line treatment of advanced triple-negative breast cancer. The European Commission granted similar approval across EU member states. Regulators are now also reviewing a supplemental filing to pair Trodelvy with Keytruda for PD-L1 positive disease. If that combination clears, Gilead’s oncology positioning moves from peripheral to central. Trodelvy alongside Merck’s Keytruda is not a side hustle. That is a potential backbone therapy on both sides of the Atlantic.
Gilead’s Q1 2026 results supported the upgrade thesis: revenue of $6.96 billion, beating estimates by roughly 1.5%. Adjusted operating margin came in at 46.9%, above expectations. Full-year product sales guidance was raised. Analysts maintain a Buy consensus with an average price target of $161.23. The stock is trading near $129. That gap between where it trades and where analysts think it belongs is the opportunity.
A July 9 non-Hodgkin lymphoma call is the next near-term catalyst. August 6 brings Q2 earnings. And the Arcellx, Ouro Medicines, and Tubulis acquisitions are adding oncology assets with real pipeline weight. The CEO called it the strongest pipeline in Gilead’s history. The acquisitions suggest management believes it too.
Now Regeneron.
REGN reported Q1 2026 revenues up 19% to $3.6 billion. Non-GAAP EPS of $9.47 beat estimates. Dupixent global net sales grew 33% to $4.9 billion. EYLEA HD U.S. net sales surged 52% to $468 million. By the numbers, this is a company performing. And yet the stock has fallen roughly 40% from its 52-week high near $821.
The reason: pipeline.
Regeneron’s fianlimab and Libtayo combination failed to significantly delay cancer progression versus Merck’s Keytruda in a Phase 3 melanoma study. One trial. The market re-rated the entire oncology pipeline lower. Citi downgraded to Neutral and cut its target to $700 from $900. At least 10 brokerages reduced price targets after the update.
The real debate with REGN is whether Dupixent can carry the business while oncology rebuilds. Dupixent keeps expanding — it now covers CSU in children aged 2 to 11, allergic fungal rhinosinusitis, and continues adding indications globally. The drug is growing in the mid-30s percentage range annually. EYLEA HD is holding up better than feared despite biosimilar pressure. With nearly 50 product candidates in clinical development, the pipeline is not empty.
But the melanoma setback matters. It reset the growth multiple and created real uncertainty about the oncology path forward. Q2 earnings will test whether Dupixent can keep the financial model intact while management rebuilds credibility. If it can, the stock at current levels may look cheap in hindsight. That is a 12-month thesis, not a near-term one.
Valuation is close. Gilead at roughly $129 trades around 17.9x earnings with fresh Buy upgrades and a $161 consensus target. Regeneron trades near $630 following its drawdown, also around 17x to 18x earnings. Both are inexpensive for large-cap biopharma. But Gilead has the near-term catalysts — HIV trial results this week, the Trodelvy EU combination filing pending, an earnings date in August — and it has fresh institutional upgrades, not ongoing cuts.
The editorial call: Gilead is the stronger opportunity today. The HSBC upgrade is grounded in specific HIV adherence data. The Trodelvy approvals are real revenue events already happening. The long-acting HIV pipeline is more durable than what the current stock price implies. Regeneron remains a high-quality business with a world-class Dupixent franchise — patient investors may eventually be rewarded. But in this window, the momentum, the catalysts, and the analyst sentiment all point toward Gilead.